Daniel O’Connell: Sure. Thanks, Eric and thanks, Colin for the question. In terms of the ALTITUDE-AD study, as we mentioned, we are in the mode of operationalizing and focused on execution. In terms of feedback that we had at CTAD interacting with the site investigators and others in the field, there was a strong demand and interest in participating in the study. So we’re optimistic that the interest in participating in research, and particularly with respect to 193, is we’re in a good moment of time for that. In terms of specific timelines, it’s just too early to say. I mean we’ve got to get sites up and running. There are a series of developments over the next 12 months that will inform more specifically what our timelines are for enrollment, but we’ll be happy to provide additional detail, when we have some visibility on where we stand in terms of enrollment and outcomes.
Colin Bristow: Great. Thanks.
Operator: Thank you. And I see we have a follow-up question from Pete Stavropoulos from Cantor Fitzgerald. Your line is open.
Pete Stavropoulos: Again, thank you for taking the follow up. Again Eric, another, I guess, very interesting presentation at CTAD. It had to do with an analysis of baseline characteristics and ARIA by — for donanemab. Just — I just want to hear your take on that data and sort of how you’re going to implement that for your Phase II, if you’re going to implement any of those factors for your Phase II?
Eric Siemers: Well, yeah, we’ve talked a lot about risk factors for ARIA. And as you know, one of the big ones is APOE4 status. And one of the interesting things that we’ve presented before is that in our six, APOE4 homozygotes, we didn’t have any cases of ARIA. So from that standpoint, I think it’s good. It’s interesting, but not surprising that some of these findings were found and in our upcoming Phase II/III study will more clearly determine whether APOE4 carrier status is a risk factor for ARIA-E. Eliminating that risk factor would obviously be really beneficial in the clinic because now there’s some recommendations that people be tested for their APOE carrier status before you begin treatment. Some clinicians, if you were an APOE4 homozygote would not — would not initiate some of the drugs that are either approved or being looked at for approval. So not having that as a liability would be really clinically, I think, a really major benefit.
Pete Stavropoulos: Okay. And some of the other factors, like anti-hypertensives? The…
Eric Siemers: Yeah. I’m sorry. It’s really difficult, at least for me to interpret those data. They’re kind of interesting. It’s a little bit of a head scratcher. I don’t think there’s anything definitive enough in there that we would change the design of our study. That’s the sort of thing that I would want to see those results replicated before we take those two seriously.
Operator: Thank you. And I’m showing no further questions. I will now turn the call back over to Alex Braun for any closing remarks.
Alex Braun: Great. Thanks, everyone, for joining us today. We did present a lot of information. So if you have any follow-up questions, we are available at the company for you. Have a great day.
Operator: Ladies and gentlemen, that does conclude our conference for today. Thank you for your participation. You may now disconnect.
